{
  "items": "12",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "biote Corp. $BTMD Stock Position Lessened by Bandera Partners LLC",
      "url": "https://www.marketbeat.com/instant-alerts/filing-biote-corp-btmd-stock-position-lessened-by-bandera-partners-llc-2025-11-25/",
      "time_published": "20251125T031513",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Bandera Partners LLC reduced its holdings in biote Corp. (NASDAQ:BTMD) by 6.2% in the second quarter, selling 151,844 shares but retaining 2,283,791 shares, making it their eighth-largest position. Despite biote beating Q2 earnings estimates with EPS of $0.22 and revenue of $47.96 million, the stock opened down 3.4%. Hedge funds and institutions now own approximately 21.68% of biote's shares, with other firms like Nuveen and Acadian increasing their stakes, while analysts currently hold a consensus \"Hold\" rating with a $6.00 target price.",
      "banner_image": "https://www.marketbeat.com/images/loading-gif?v=2",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.925449"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.730399"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.804894"
        }
      ],
      "overall_sentiment_score": -0.22001,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "BTMD",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.246663",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "biote (BTMD) Q3 2025 Earnings Call Transcript",
      "url": "https://www.fool.com/earnings/call-transcripts/2025/11/06/biote-btmd-q3-2025-earnings-call-transcript/",
      "time_published": "20251120T000905",
      "authors": [
        "Motley Fool Transcribing"
      ],
      "summary": "Biote (BTMD) reported a Q3 2025 revenue decrease of 6.7% to $48 million, primarily due to slower procedure business, though dietary supplement revenue grew 8.4%. The company is focused on rebuilding its commercial organization, enhancing sales force effectiveness, and made significant progress in settling financial agreements with Marcy and Dr. Gary Donovitz, resulting in substantial cash flow savings and an extended non-compete for Dr. Donovitz. Despite an elevated attrition rate in practitioners and ongoing sales force transformation impacting procedure volumes, Biote reiterated its 2025 revenue guidance above $190 million and adjusted EBITDA above $50 million, anticipating improvements from strategic initiatives.",
      "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Fmisc-assets%2Ffool-transcripts-logo.png&w=3840&op=resize",
      "source": "The Motley Fool",
      "category_within_source": "General",
      "source_domain": "The Motley Fool",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.916950"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.735507"
        }
      ],
      "overall_sentiment_score": 0.081898,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BTMD",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.094327",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "biote Corp. (NASDAQ:BTMD) Q3 2025 Earnings Call Transcript",
      "url": "https://www.insidermonkey.com/blog/biote-corp-nasdaqbtmd-q3-2025-earnings-call-transcript-1641650/",
      "time_published": "20251107T081800",
      "authors": [
        "NULL"
      ],
      "summary": "Biote Corp. (NASDAQ:BTMD) reported its Q3 2025 earnings, beating expectations with an EPS of $0.22 against a forecast of $0.05. The company highlighted strategic progress, including rebuilding its commercial organization to accelerate new provider growth and maximizing value from top-tier clinics despite a 6.7% revenue decrease primarily due to procedure revenue challenges. Biote also announced significant cash flow savings by amending settlement agreements with Marci and Dr. Gary Donovitz for share repurchases.",
      "banner_image": "https://imonkey-blog.imgix.net/blog/wp-content/uploads/2023/11/02215633/BTMD-insidermonkey-1698976591540.jpg?auto=format&fit=clip&expires=1796342400&width=480&height=269",
      "source": "Insider Monkey",
      "category_within_source": "General",
      "source_domain": "Insider Monkey",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.911029"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.736071"
        },
        {
          "topic": "finance",
          "relevance_score": "0.610351"
        }
      ],
      "overall_sentiment_score": 0.254794,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BTMD",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.251657",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Biote Director Steven J. Heyer Resigns",
      "url": "https://www.tipranks.com/news/company-announcements/biote-director-steven-j-heyer-resigns",
      "time_published": "20251102T112943",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Steven J. Heyer has resigned from biote Corp.'s Board of Directors, effective June 2, 2025. His resignation was not due to disagreements with the company's operations, and a replacement has not yet been appointed. Spark, TipRanks' AI Analyst, rates BTMD as Neutral, noting strong revenue and profit growth but also financial risks and a negative equity position.",
      "banner_image": null,
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.936298"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.818307"
        }
      ],
      "overall_sentiment_score": -0.139172,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BTMD",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.107517",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Biote Reduces Marc Beer\u2019s Salary Amid Transition",
      "url": "https://www.tipranks.com/news/company-announcements/biote-reduces-marc-beers-salary-amid-transition",
      "time_published": "20251102T112943",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Biote Corp. Executive Chairman Marc Beer transitioned to part-time employment on April 1, 2025, as part of a leadership transition plan. Consequently, his annual salary was reduced from $490,000 to $196,000, effective retroactively from the transition date. He is expected to become Non-Executive Chairman by the end of the third quarter of 2025.",
      "banner_image": null,
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.908600"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.804539"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.719833"
        }
      ],
      "overall_sentiment_score": 0.014782,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "BTMD",
          "relevance_score": "0.315653",
          "ticker_sentiment_score": "0.010875",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "biote Corp. SEC 10-K Report",
      "url": "https://www.tradingview.com/news/tradingview:65d7a1051d398:0-biote-corp-sec-10-k-report/",
      "time_published": "20251102T112943",
      "authors": [],
      "summary": "Biote Corp. has released its annual Form 10-K report detailing significant financial growth, strategic initiatives, and operational highlights. The company reported a total revenue of $197.2 million and a net income of $0.05 million, driven by an expansion of its market presence and enhancement of operational efficiency through strategic acquisitions and vertical integration. Facing challenges such as market acceptance and regulatory risks, Biote plans to expand its U.S. geographic footprint and explore international expansion.",
      "banner_image": null,
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.943954"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.816493"
        },
        {
          "topic": "finance",
          "relevance_score": "0.701981"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.607953"
        }
      ],
      "overall_sentiment_score": 0.265879,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BTMD",
          "relevance_score": "0.960645",
          "ticker_sentiment_score": "0.285334",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Biote Corp. Stock Plummets to New 52-Week Low of $2.65",
      "url": "https://www.marketsmojo.com/news/stocks-in-action/biote-corp-stock-plummets-to-new-52-week-low-of-265-3659222",
      "time_published": "20251030T185600",
      "authors": [],
      "summary": "Biote Corp., a microcap company in the hospital sector, has reached a new 52-week low of USD 2.65, reflecting a 58.54% decline in its stock performance over the past year. The company faces significant financial challenges, including a negative book value, a concerning debt-to-equity ratio, and a drop in net profit and inventory turnover. Its market capitalization stands at USD 176 million with a P/E ratio of 5.00, despite these financial hurdles.",
      "banner_image": null,
      "source": "Markets Mojo",
      "category_within_source": "General",
      "source_domain": "Markets Mojo",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.935740"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.809863"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.703200"
        }
      ],
      "overall_sentiment_score": -0.845496,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "BTMD",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.839435",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Biote Corp. sees $155,387 in stock acquisitions by Guines LLC",
      "url": "https://www.investing.com/news/insider-trading-news/biote-corp-sees-155387-in-stock-acquisitions-by-guines-llc-93CH-3980313",
      "time_published": "20250410T044500",
      "authors": [
        "Investing.com"
      ],
      "summary": "Guines LLC acquired a significant number of Biote Corp. (NASDAQ: BTMD) Class A common shares over two consecutive days, totaling $155,387. These transactions increased Guines LLC's holdings to 4,156,426 shares. This insider buying activity follows a significant stock decline and recent underperformance in reported earnings for BioTE Corp.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_pile_69x52._800x533_L_1419494209.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.809530"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.718171"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.617717"
        }
      ],
      "overall_sentiment_score": 0.285971,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BTMD",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.255431",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "biote Corp. (BTMD): Insider Were Buying In Q1 2025",
      "url": "https://finance.yahoo.com/news/biote-corp-btmd-insider-were-193317288.html",
      "time_published": "20250402T000942",
      "authors": [
        "Nina Zdinjak"
      ],
      "summary": "Biote Corp. (NASDAQ:BTMD) saw significant insider buying in Q1 2025, with five insiders, including the CEO, acquiring $2.79 million worth of shares. Despite a year-to-date stock drop, the company reported increased revenue and gross profit margin for 2024, driven by procedure revenue and cost management. Analysts rate BTMD as a \"Strong Buy\" with a target price suggesting over 100% upside.",
      "banner_image": null,
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.935515"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.843887"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.731697"
        },
        {
          "topic": "finance",
          "relevance_score": "0.632389"
        },
        {
          "topic": "economy_macro",
          "relevance_score": "0.630764"
        }
      ],
      "overall_sentiment_score": 0.380585,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BTMD",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.361860",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Biote reaches $60 million settlement with founder\u2019s ex-wife over SPAC deal",
      "url": "https://www.dallasnews.com/business/2024/07/08/biote-reaches-60-million-settlement-with-founders-ex-wife-over-spac-deal/",
      "time_published": "20240708T150900",
      "authors": [
        "Irving Mejia-Hilario"
      ],
      "summary": "Biote has reached a $60 million settlement with its founder\u2019s ex-wife, Marci Donovitz, stemming from a 2022 SPAC merger that allegedly diluted founding members' ownership stakes and provided little cash for the deal. As part of the settlement, Biote will repurchase all 8.3 million of Donovitz\u2019s shares at $7.23 each over three years. This follows a previous settlement with founder Gary Donovitz and highlights increasing scrutiny on SPACs by the SEC.",
      "banner_image": null,
      "source": "Dallas News",
      "category_within_source": "General",
      "source_domain": "Dallas News",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "1.000000"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.936276"
        },
        {
          "topic": "finance",
          "relevance_score": "0.844249"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.735992"
        }
      ],
      "overall_sentiment_score": -0.286558,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "BTMD",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.254829",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Cooley Sued for \u2018Tricking\u2019 Biote Founder in SPAC Deal Gone South",
      "url": "https://news.bloomberglaw.com/business-and-practice/cooley-sued-over-tricking-allegations-in-spac-deal-gone-south",
      "time_published": "20240606T210500",
      "authors": [
        "Roy Strom"
      ],
      "summary": "Law firm Cooley LLP is facing a lawsuit alleging it \"tricked\" the founder of Biote Holdings in a SPAC merger that diluted the founder's holdings. The suit, filed in Delaware Chancery Court, claims Cooley lawyers and other defendants failed to disclose material aspects of the 2022 merger between Biote Holdings and Haymaker Acquisition Corp. III.",
      "banner_image": null,
      "source": "Bloomberg Law News",
      "category_within_source": "General",
      "source_domain": "Bloomberg Law News",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.919171"
        },
        {
          "topic": "finance",
          "relevance_score": "0.825249"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.715034"
        }
      ],
      "overall_sentiment_score": -0.403858,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "BTMD",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.424380",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Biote settles litigation with founder, repurchases shares",
      "url": "https://www.investing.com/news/company-news/biote-settles-litigation-with-founder-repurchases-shares-93CH-3405052",
      "time_published": "20240429T011016",
      "authors": [
        "Investing.com"
      ],
      "summary": "Biote Corp. (NASDAQ: BTMD) has settled its litigation with founder Dr. Gary S. Donovitz and will repurchase all his 18.4 million shares for approximately $76.9 million over three years. This agreement allows Biote to focus on its strategic goals, and InvestingPro data highlights the company's strong revenue growth, gross profit margin, and expected net income growth. The first share repurchase tranche of $32.2 million has already been completed.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.909101"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.817692"
        },
        {
          "topic": "finance",
          "relevance_score": "0.701801"
        }
      ],
      "overall_sentiment_score": 0.448031,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "BTMD",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.414274",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}